Tim Beyers

There will be possibly some approval delays.

But over the long term, we still should like emergent science biotechs because those are still necessary and will come to market.

Got it.

Okay.

We'll keep our eyes on this.

Fools, let us know what you think and what emerging biotechs you're investing in.

Up next, three broken breakers we still believe in.

Welcome back to Motley Fool Money.

We like dark clouds we can see through.

If you don't know what that principle means, I'd like to introduce you to David Gardner's new book on Rule Breaker Investing.

Dark clouds we can see through means, and it's a long-held principle of David's in Rule Breakers,

We aren't trying to buy the low, but we love it when a company that we really believe in that has significant Rule Breaker traits gets punished for reasons that maybe are temporary or maybe are unfair.

We like these companies as Rule Breakers that may have taken a backward step

for reasons that are partially their own fault, but maybe not completely.

There are dark clouds.

We can see through them, and we're willing to stick it out and wait until the sunny skies return.

We're going to talk about three of them.

Rick, I'm going to start with you.

We're going to start with the trade desk, because boy, is it just raining on their boardroom?

What's going on here?